Alejandra Comins-Boo

No ORCID on file · 3 papers in corpus
observational 2026
Do Serologic Domains of the 2023 ACR/EULAR Classification Criteria for Antiphospholipid Syndrome Define Distinct Clinical Subgroups During Pregnancy?
International journal of molecular sciences ·doi:10.3390/ijms27146100

To evaluate the clinical applicability of the 2023 ACR/EULAR serologic classification criteria for antiphospholipid syndrome (APS) in a cohort of pregnant women across the APS spectrum, and to assess the association between serologic burden…

observational 2026
The impact of antinuclear antibodies and complement levels in the prognosis of pregnant women within the antiphospholipid syndrome spectrum
Frontiers in immunology ·doi:10.3389/fimmu.2026.1818605

INTRODUCTION: To assess the prevalence and clinical impact of antinuclear antibodies (ANA) and low complement levels on fetal-maternal outcomes in pregnant women within the spectrum of obstetric antiphospholipid syndrome (APS). METHODS: A …

observational 2022
Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) Predict the Obstetric Outcome in Antiphospholipid Antibody Carriers? A Single-Center Study
Clinical reviews in allergy & immunology ·doi:10.1007/s12016-021-08915-9

The adjusted Global Antiphospholipid Syndrome (APS) Score (aGAPSS) is a tool proposed to quantify the risk for antiphospholipid antibody (aPL)-related clinical manifestations. However, aGAPSS has been validated mainly for thrombotic events …